Investor Presentation H1 2023

17 Investor presentation First six months of 2023 Financial results - First six months of 2023 Novo NordiskⓇ In DKK million Sales Gross profit Gross margin Sales and distribution costs First six months of 2023 First six Change Change 107,667 91,629 85.1% (26,754) months of 2022 83,296 (reported) (CER) 29% 30% 70,310 30% 32% 84.4% (21,023) 27% 28% Percentage of sales 24.8% 25.2% Research and development costs (13,855) (10,329) 34% 34% Percentage of sales 12.9% 12.4% Administration costs (2,143) (1,961) 9% 10% Percentage of sales 2.0% 2.4% Other operating income and expenses 18 541 (97%) (96%) Operating profit 48,895 37,538 30% 32% Operating margin 45.4% 45.1% Financial items (net) 96 (2,824) Profit before income tax 48,991 34,714 41% Income taxes (9,749) (7,186) 36% Effective tax rate 19.9% 20.7% Net profit 39,242 27,528 43% Diluted earnings per share (DKK) 17.41 12.08 44% CER: Constant exchange rates

View entire presentation